Preparing for China · patient guide

Acute leukemia care: the records a specialist needs first

For acute leukemia, a specialist first needs records that establish the exact diagnosis and subtype, the genetic and molecular features of the disease, what treatment has already been given and how the patient is responding now. A referral letter, the diagnostic reports behind the leukemia diagnosis and the current treatment summary matter more than a complete archive sent at once.

Go to the practical guidance ↓
AI illustration: A doctor in a white coat consulting with a patient in a beige sweater at a desk with documents.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Start with the diagnosis, not the whole file

Acute leukemia is not one disease. Acute myeloid leukemia and acute lymphoblastic leukemia are different illnesses with different treatment routes, and within each there are subtypes defined by laboratory and genetic findings. A specialist reviewing an overseas patient cannot judge suitability for care in China from a discharge summary alone. The first useful package is the evidence that establishes what the patient actually has.

The practical starting point is the report that first confirmed the diagnosis, plus the laboratory work that classified it. If the patient was diagnosed at one hospital and treated at another, send the diagnostic reports from the first and the treatment records from the second. A short cover note listing the patient's age, the diagnosis as written, the date of diagnosis and the single most important question helps the receiving team read the file in the right order.

This is a records question, not a travel question. Nothing about flights or hotels changes what the hematology team needs to see. The clinical picture comes first; practical arrangements follow only if the hospital indicates that an assessment is appropriate.

The laboratory and genetic records that define the disease

The treating team will want the reports behind the diagnosis, not just the conclusion printed on a summary. For acute leukemia this generally means the bone marrow reports, blood count and blood film findings, and the immunophenotyping that identifies the cell lineage. Flow cytometry reports and, where performed, immunohistochemistry or pathology reports belong in the first batch.

Genetic and molecular results are central to how acute leukemia is classified and managed. Cytogenetics, fluorescence in situ hybridization studies, and molecular testing such as polymerase chain reaction or next-generation sequencing panels carry information that can change the treatment approach. Send the full reports, including the variant details and any interpretive comments, rather than a line in a discharge letter saying a mutation was found.

If some of these tests were never done, that is itself useful information. The receiving clinician can then say whether further testing would be needed and whether it could be arranged locally before any travel. Do not assume a test must be repeated in China; ask the team what it would accept from the referring laboratory and what it would need to repeat.

A common gap is that patients send the final diagnosis but not the raw laboratory reports. Another is sending reports in a language the receiving team cannot read without a translation. Ask the hospital in advance what language and format it accepts for laboratory documents, and keep original scanned copies alongside any translation.

Treatment history: what was given, when, and how the disease responded

The second core record is a clear treatment chronology. For each course of chemotherapy or other therapy, the specialist needs the regimen used, the dates, the doses where available, and the response assessment that followed. Induction, consolidation and any maintenance phases should be distinguishable rather than merged into one line.

Response matters as much as treatment. Bone marrow reports after treatment, measurable residual disease results where they exist, and imaging or clinical notes describing remission status all help the receiving team understand where the patient stands. If the patient relapsed, the date and the evidence of relapse are important. If treatment was stopped or changed because of toxicity, that reason should be visible in the records.

Transfusion history, infection episodes and any intensive care admissions are relevant to safety planning, but they do not need to lead the file. Put them in a chronological summary that the treating team can scan, with the underlying reports attached. A one-page timeline built by the patient or family is acceptable as a guide, provided it is clearly labelled as a summary and not a substitute for the source documents.

Ask the current treating team for a referral letter. A letter from the clinician who knows the case, stating the diagnosis, treatment given, current status and the reason for seeking an opinion, is often the single most useful document in the package.

Current status, medicines and the question you want answered

Records describe the past; the receiving team also needs the present. Include recent blood counts with dates, current medicines and doses, allergies, active infections or fevers, and any recent hospital admissions. If the patient is currently receiving treatment, say so plainly and give the date of the next planned course. This affects whether a records review is realistic now or whether the question should wait.

Be specific about what you are asking. "Is treatment in China possible?" is too broad for a useful reply. Better questions are whether the recorded diagnosis and genetic findings support a particular treatment approach, whether the patient's current status makes an assessment in China reasonable, and what additional information the team would need before giving a view. A records-based opinion can address these; it cannot promise hospital acceptance or a clinical outcome.

It also helps to state the patient's functional status in ordinary terms, such as whether they are at home, in hospital, or able to travel for assessment. Do not send a complete medical archive through an initial web form. A brief summary with the diagnosis, treatment history and main question is enough to begin, and the team can then explain how to share the fuller records securely.

What a records review can and cannot settle

A hematology specialist reviewing documents from abroad can form a view on the diagnosis as recorded, identify missing information, comment on whether the treatment history is consistent with the stated subtype, and indicate what the next clinical step might be. That is genuinely useful before deciding whether to pursue care in China.

It cannot replace an in-person assessment, confirm fitness for a specific treatment, or guarantee that a hospital will accept the patient. Acute leukemia care depends on current blood counts, infection status, organ function and the patient's overall condition, which change quickly. Any plan discussed from records remains provisional until the treating hospital assesses the patient directly.

This boundary is not a reason to delay. If the patient is unwell now, local urgent care takes priority over an overseas enquiry. Records can be assembled in parallel, but worsening symptoms, fever or bleeding need assessment where the patient is, not a wait for an international reply.

A practical first step

Gather the diagnostic reports, the classification and genetic results, a treatment chronology with response assessments, a referral letter and a short statement of the current status and question. A free initial enquiry with ChinaSpecialistCare can check whether the available records cover the main points, point out obvious gaps and suggest the relevant next step; it is not a diagnosis and does not promise acceptance. If a records-based specialist opinion is wanted, a proxy consultation can be discussed, but it is optional and not a prerequisite for care. The hospital decides suitability.

For background on how acute leukemia is assessed and treated, see the acute leukemia care reference and the hematology specialty page.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. hematology
  2. Related treatment reference
  3. NCI: Adult Acute Myeloid Leukemia Treatment (PDQ)
  4. NCI: Adult Acute Lymphoblastic Leukemia Treatment (PDQ)
  5. WHO Classification of Tumours: Haematolymphoid Tumours

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.